Remarkably, patients with metastatic BLCA treated with combination therapy of EFNB2 inhibition and pembrolizumab had better OS and improved treatment responses than those receiving anti-PD-1/PD-L1 monotherapy (24). This evidence concerns the gene PDCD1 and bladder transitional cell carcinoma.